Ghost Tree Capital’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Ghost Tree Capital’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-275,000	Closed	-$6.43M	–	67
2021 Q1	$6.43M	Sell	275,000 -350,000	-56%	-$10.6M	1.51%	23
2020 Q4	$18M	Sell	625,000 -100,000	-14%	-$2.52M	4.01%	7
2020 Q3	$14.7M	Buy	725,000 +75,000	+12%	+$1.83M	4.25%	7
2020 Q2	$19.5M	Hold	650,000	–	–	5.15%	4
2020 Q1	$20.4M	Buy	650,000 +74,500	+13%	+$2.59M	5.42%	5
2019 Q4	$27.1M	Buy	+575,500	New	+$16.6M	5.16%	4

Other funds holding CNST

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

OPU

Omni Partners US Irvine, California $1.95B AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ghost Tree Capital's CNST Position: Q2 2021 in Review

Ghost Tree Capital sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 275,000 shares — an estimated $6.43M sold.

Ghost Tree Capital first reported a position in CNST in Q4 2019 and held it in 6 quarters. The position peaked at $27.1M in Q4 2019. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

Ghost Tree Capital reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Ghost Tree Capital sold 275,000 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $6.43M.
Ghost Tree Capital first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2019 and held it in 6 quarters.
Ghost Tree Capital's Constellation Pharmaceuticals, Inc. position peaked at $27.1M in Q4 2019.
153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Ghost Tree Capital's 13F filing for Q2 2021, filed 11 Aug 2021.